CTOR Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
1.5M
-10.4%
1.7M
-57.7%
3.9M
0
0
Cost of Revenue
491.8K
+49.6%
328.9K
-58.3%
789.2K
0
0
Gross Profit
1.0M
-25.1%
1.3M
-57.6%
3.2M
0
0
Operating Expenses
9.7M
-67.6%
30.0M
+256.3%
8.4M
+78.4%
4.7M
-4.7%
4.9M
R&D
218.5K
-79.8%
1.1M
+6.0%
1.0M
-5.4%
1.1M
+14.7%
938.3K
SG&A
7.8M
-67.1%
23.6M
+246.7%
6.8M
+87.5%
3.6M
-9.3%
4.0M
Operating Income
-8716817
+69.5%
-28613595
-444.8%
-5252276
-11.5%
-4711512
+4.7%
-4944961
EBITDA
-8716817
+70.1%
-29187033
-523.8%
-4678838
+0.7%
-4711512
+4.7%
-4944961
Net Income
-8923846
+66.5%
-26609695
-380.8%
-5534069
-10.8%
-4996656
+7.0%
-5369956
EPS (Basic)
$-0.08
+70.4%
$-0.27
-350.0%
$-0.06
+0.0%
$-0.06
+25.0%
$-0.08
EPS (Diluted)
$-0.08
+70.4%
$-0.27
-350.0%
$-0.06
+0.0%
$-0.06
+25.0%
$-0.08
Shares (Diluted)
107.9M
+7.9%
100.0M
+14.4%
87.5M
+11.5%
78.4M
+9.6%
71.6M
Citius Oncology (CTOR) โ€” Financials